Methods and materials for treating cancer
This document provides methods and materials for treating cancer. For example, methods and materials for using oncolytic viruses (e.g., replication-competent vesicular stomatitis viruses) to treat cancer are provided. Replication-competent oncolytic viruses (e.g., replication-competent oncolytic vesicular stomatitis viruses), nucleic acid molecules encoding a replication-competent oncolytic virus (e.g., replication-competent oncolytic vesicular stomatitis virus), methods for making replication-competent oncolytic viruses (e.g., replication-competent oncolytic vesicular stomatitis viruses), methods for using replication-competent oncolytic viruses (e.g., replication-competent oncolytic vesicular stomatitis viruses) to treat cancer, cancer neoantigens, nucleic acids encoding a cancer neoantigen, and methods for stimulating immune cells (e.g., cytotoxic T lymphocytes) to kill cancer cells also are provided.
1 . A method for treating cancer in a mammal, wherein said method comprises administering, to said mammal, (a) a replication-competent oncolytic virus and (b) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1 or nucleic acid encoding said polypeptide, and wherein said cancer comprises melanoma or hepatocellular carcinoma.
2 . The method of claim 1 , wherein said mammal is a human.
3 . The method of claim 1 , wherein said virus is a vesicular stomatitis virus.
4 . The method of claim 1 , wherein said polypeptide is a full length CSDE1 P5S polypeptide.
5 . The method of claim 1 , wherein said polypeptide comprises less than 100 amino acid residues.
6 . The method of claim 1 , wherein said polypeptide comprises less than 100 amino acid residues of a full length CSDE1 P5S polypeptide.
7 . The method of claim 1 , wherein said polypeptide comprises a cell penetrating amino acid sequence.
8 . The method of claim 1 , wherein said method comprises administering said polypeptide.
9 . The method of claim 1 , wherein said method comprises administering said nucleic acid.
10 . A replication-competent oncolytic virus comprising nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:1 or comprising a nucleic acid sequence that is a template for said nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:1.
11 . The virus of claim 10 , wherein said virus is selected from the group consisting of a vesicular stomatitis virus, an adenovirus, and a herpesvirus.
12 . The virus of claim 10 , wherein said nucleic acid encoding encodes a full length CSDE1 P5S polypeptide.
13 . The virus of claim 10 , wherein said nucleic acid encodes a polypeptide that comprises less than 100 amino acid residues of a full length CSDE1 P5S polypeptide.
14 . A composition comprising (a) a substantially pure polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1 and (b) an adjuvant.
15 . A replication-competent vesicular stomatitis virus comprising an RNA molecule, wherein said RNA molecule comprises a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV N polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV P polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV M polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV G polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding the amino acid sequence set forth in SEQ ID NO:1, and a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV L polypeptide, wherein said positive sense transcript encoding said VSV N polypeptide, said positive sense transcript encoding said VSV P polypeptide, said positive sense transcript encoding said VSV M polypeptide, said positive sense transcript encoding said VSV G polypeptide, and said VSV L polypeptide are each set forth within the nucleotide sequence of SEQ ID NO:16.
16 . A composition comprising (a) the replication-competent vesicular stomatitis virus of claim 15 and (b) a biologically compatible solution or a pharmaceutically acceptable delivery vehicle.
17 . A nucleic acid molecule comprising a nucleic acid strand comprising a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV N polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV P polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV M polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV G polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding the amino acid sequence set forth in SEQ ID NO:1, and a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV L polypeptide, wherein said positive sense transcript encoding said VSV N polypeptide, said positive sense transcript encoding said VSV P polypeptide, said positive sense transcript encoding said VSV M polypeptide, said positive sense transcript encoding said VSV G polypeptide, and said VSV L polypeptide are each set forth within the nucleotide sequence of SEQ ID NO:16.